An Act prohibiting discrimination against 340b drug discount program participants
Take action
Record your position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Overview
This bill aims to prevent insurance companies in Massachusetts from unfairly denying coverage or charging higher rates to individuals who rely on drugs purchased through the 340b drug discount program. The program provides discounted medications to healthcare providers who serve patients with low incomes and other vulnerable populations. By prohibiting discrimination against participants, the bill seeks to ensure equitable access to essential medications for those who need them most. This legislation focuses on protecting patients’ access to affordable medications.
Key provisions
- Prohibits insurance companies from denying coverage for drugs purchased through the 340b program.
- Prevents insurers from charging higher premiums or cost-sharing amounts to 340b participants.
- Ensures that 340b drugs are covered at the same rates as other medications.
- Addresses potential discrimination in coverage decisions related to 340b drugs.
- Supports access to affordable medications for vulnerable populations.
Who is affected
- Individuals with low incomes
- Patients receiving care at healthcare providers participating in the 340b program
- Insurance companies in Massachusetts
- Healthcare providers
- Pharmaceutical manufacturers
Notable changes
- The bill seeks to clarify and strengthen existing protections for 340b drug discount program participants.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
22 on record
Primary sponsor
Daniel Cahill
Cosponsors
Daniel Cahill
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours